The University of Tokyo · Medicine
Professor Kotaro Sugawara's research lab focuses on translational oncology, particularly in gastrointestinal cancers such as esophageal and gastric carcinoma. The lab investigates novel therapeutic strategies, including oncolytic virus therapy combined with immune checkpoint inhibitors, to enhance antitumor immunity and overcome immunosuppressive microenvironments. A key emphasis is placed on identifying and validating predictive biomarkers—especially inflammatory and nutritional markers like GNRI, CRP-derived indices, and Glasgow Prognostic Score—for survival outcomes and treatment response in patients undergoing surgery or chemoradiotherapy. The lab also explores preoperative pulmonary and nutritional status as critical determinants of postoperative survival, aiming to improve patient selection and outcomes in esophageal cancer.
Figures are computed from collected data and may differ slightly.
Oncolytic virus therapy can increase the immunogenicity of tumors and remodel the immunosuppressive tumor microenvironment, leading to an increased antitumor response to immune-checkpoint inhibitors. Here, we investigated the therapeutic potential of G47Δ, a third-generation oncolytic herpes simplex virus type 1, in combination with immune-checkpoint inhibitors using various syngeneic murine subcutaneous tumor models. Intratumoral inoculations with G47Δ and systemic anti-cytotoxic T-lymphocyte-a
GNRI is useful for predicting survival and oncological outcomes in GC patients.
Various inflammatory or nutritional markers, especially those derived from CRP, are useful for predicting survival outcomes of ESCC patients. The predictive capabilities of these indices were augmented when used in combination with pStage.
Salvage esophagectomy (SALV) is potentially beneficial for patients with residual or relapsed esophageal carcinoma after definitive chemoradiotherapy (dCRT), although preoperatively identifying good candidates for SALV remains difficult. We investigated the prognostic impacts of inflammatory and nutritional status in patients undergoing SALV after dCRT. Forty-seven SALV patients were retrospectively reviewed, of whom 46 (98%) had squamous cell carcinoma and 1 (2%) adenocarcinoma. Possible progno
The survival outcomes of patients with relapsed EC remain poor. Surgical treatments could provide survival benefits for patients with recurrent EC, especially for patients with OM.
Open papers in the app to read, cite, and organize with AI.
